Aviva’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-42,095
Closed -$1.22M 1000
2021
Q1
$1.22M Buy
+42,095
New +$1.18M 0.01% 817

Other funds holding NGM

Aviva's NGM Position: Q2 2021 in Review

Aviva sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2021, closing a stake of 42,095 shares — an estimated $1.22M sold.

Aviva first reported a position in NGM in Q1 2021 and held it in 1 quarter. The position peaked at $1.22M in Q1 2021. 107 funds tracked by Wall St. Rank hold NGM as of Q2 2021.

  • Aviva reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Aviva sold 42,095 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $1.22M.
  • Aviva first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Aviva's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.22M in Q1 2021.
  • 107 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.